证券代码：872925 证券简称：锦好医疗 公告编号：2023-071 惠州市锦好医疗科技股份有限公司 第二届董事会第二十七次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2023 年 8 月 25 日 2.会议召开地点：公司会议室 5.会议主持人：王敏先生 6.会议列席人员：监事及高级管理人员 7.召开情况合法、合规、合章程性说明： 会议应出席董事 7 人，出席和授权出席董事 7 人。 本次会议的召集、召开程序符合《公司法》、《公司章程》和《董事会议事规 则》的相关规定。 （二）会议出席情况 董事袁英红因工作原因以通讯方式参与表决。 董事李忠轩因工作原因以通讯方式参与表决。 二、议案审议情况 （一）审议通过《关于<2023 年半年度报告及摘要>的议案》 1.议案内容： 根据相关法律、法规要求，公司编制了 2023 年半年度报告及摘要，具体内 3.会议召开方式：现场与通讯方式相结合 4.发出董事会会议通知的时间和方式：2023 ...

证券代码：872925 证券简称：锦好医疗 公告编号：2023-079 惠州市锦好医疗科技股份有限公司 关于向银行申请综合授信额度的公告 公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法 律责任。 一、基本情况 惠州市锦好医疗科技股份有限公司（以下简称公司）因业务发展需要，拟向招商 银行股份有限公司惠州分行申请不超过（含）人民币 5,000 万元的授信额度，期限为 一年，公司实际控制人、控股股东王敏先生、股东王芳女士提供连带责任担保，具体 授信事项以银行审批和最终签订的相应合同为准。 二、审批决策程序 公司于 2023 年 8 月 25 日召开第二届董事会第二十七次会议，审议通过了《关于 公司向招商银行股份有限公司惠州分行申请授信的议案》，同意公司向招商银行股份 有限公司惠州分行申请不超过（含）人民币 5,000 万元的授信额度。该议案尚需提交 公司股东大会审议。 三、申请授信额度的必要性以及对公司的影响 公司本次申请授信额度是根据公司发展战略及未来经营计划需要，通过银行授信 的融资方式为自身发展补充流动资金，对公司 ...

证券代码：872925 证券简称：锦好医疗 公告编号：2023-072 惠州市锦好医疗科技股份有限公司 第二届监事会第二十次会议决议公告 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2023 年 8 月 25 日 2.会议召开地点：公司会议室 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 1.议案内容： 根据相关法律、法规要求，公司编制了 2023 年半年度报告及摘要，具体内 容详见公司同日在北京证券交易所信息披露平台(www.bse.cn)披露的《2023 年 半年度报告》（公告编号：2023-074）和《2023 年半年度报告摘要》（公告编号： 2023-075）。 2.议案表决结果：同意 3 票；反对 0 票；弃权 0 票。 3.会议召开方式：现场会议 4.发出监事会会议通知的时间和方式：2023 年 8 月 15 日以书面方式发出 5.会议主持人：黄小华先生 6.召开情况合法、合规、合章程性说明： 本次会议的召集、召开与表决符合《公司法》等相关法律、法规和《公司章 程》的规定 ...

法律意见书 北京大成(广州)律师事务所 关于惠州市锦好医疗科技股份有限公司 2022 年股票期权与限制性股票激励计划 注销部分股票期权、调整首次授予及预留授予股票 期权数量和行权价格的 法律意见书 大成 DENTONS 大成 is Dentons' Preferred Law Firm in China. www.dentons.com 广州市天河区珠江东路 6 号广州周大福金融中心 14 层、15 层 电话: +86 20 8527 7000 传真: +86 20 8527 7002 二〇二三年八月 法律意见书 北京大成(广州)律师事务所 关于惠州市锦好医疗科技股份有限公司 2022 年股票期权与限制性股票激励计划 注销部分股票期权、调整首次授予及预留授予股票期权数量和行权 价格的法律意见书 致:惠州市锦好医疗科技股份有限公司 北京大成(广州)律师事务所(以下简称"本所")接受惠州市锦好医疗科技 股份有限公司(以下简称"锦好医疗"或者"公司")的委托,担任锦好医疗实施 2022 年股票期权与限制性股票激励计划(以下简称"本次股权激励计划"或"本激励计 划"）相关事宜的专项法律顾问。本所律师根据《中华人民共和 ...

证券代码：872925 证券简称：锦好医疗 公告编号：2023-078 公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法 律责任。 惠州市锦好医疗科技股份有限公司（以下简称"公司"）于 2023 年 8 月 25 日召开 第二届董事会第二十七次会议和第二届监事会第二十次会议，分别审议通过了《关于调 整公司 2022 年股权激励计划首次及预留授予股票期权授予数量与行权价格的议案》， 对公司 2022 年股权激励计划（以下简称"本次激励计划"）首次及预留授予股票期权 授予数量与行权价格进行调整，现将相关内容公告如下： 一、本次激励计划已履行的相关审批程序 1、2022 年 3 月 25 日，公司召开第二届董事会第十五次会议，审议《关于<惠州 市锦好医疗科技股份有限公司 2022 年股权激励计划（草案）>的议案》、《关于公司 2022 年股权激励计划授予的激励对象名单的议案》、《关于制定<惠州市锦好医疗科 技股份有限公司 2022 年股权激励计划实施考核管理办法>的议案》、《关于与激励对 象签署<股权激励计划股票期权授予协 ...

证券代码：872925 证券简称：锦好医疗 公告编号：2023-077 惠州市锦好医疗科技股份有限公司 关于注销 2022 年股权激励计划部分股票期权的公告 公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责 任。 年股权激励计划预留权益授予的激励对象名单的议案》。 8、2022 年 12 月 5 日至 2022 年 12 月 14 日，公司对拟认定核心员工的名单和预 留股票期权拟授予激励对象的名单在北京证券交易所网站及公司内部公示栏进行了 公示。在公示期内，公司监事会未收到员工对本次拟激励对象名单提出的异议。公司 监事会于 2022 年 12 月 15 日披露了《关于监事会对拟认定核心员工及预留权益授予 激励对象名单的核查意见公告》。 惠州市锦好医疗科技股份有限公司（以下简称"公司"）于 2023 年 8 月 25 日召 开第二届董事会第二十七次会议和第二届监事会第二十次会议，审议通过了《关于拟 注销 2022 年股权激励计划部分股票期权的议案》。本次公司拟注销 1.4 万份股票期 权，现将有关事项说明如下： 一 ...

Business Expansion and Development - In April 2023, Jinghao Medical's first phase of the Smart Medical Industrial Park was completed and officially put into operation, serving as a high-quality hearing aid production base and R&D center[5]. - In May 2023, Jinghao Medical opened two new hearing aid stores in Zhongshan Xiaolan and Foshan Daliang, marking the company's expansion into major cities across the country[4]. - The company aims to establish itself as a leading domestic hearing aid manufacturer through its new industrial park[5]. - The company has established a strong presence in over 90 countries, with overseas sales accounting for approximately 90% of its main business revenue[32]. - The company plans to expand its market presence in Asia-Pacific, Europe, and the Middle East while enhancing its online sales channels[35]. - The company has successfully expanded its sales channels and improved its domestic operational model, leading to a gradual acceleration in business expansion[66]. - The company has established 9 domestic specialty stores, gradually expanding its business coverage in major cities[65]. Financial Performance - The company's operating revenue for the current period reached ¥100,799,557.55, representing a 9.32% increase compared to ¥92,205,975.82 in the same period last year[26]. - The net profit attributable to shareholders decreased by 26.39% to ¥15,118,968.16 from ¥20,539,424.47 year-on-year[26]. - The company achieved a net cash flow from operating activities of ¥22,908,599.59, a significant increase of 206.74% compared to ¥7,468,514.74 in the previous year[28]. - Total assets increased by 1.55% to ¥424,152,377.56, while total liabilities rose by 5.48% to ¥55,805,495.37[27]. - The company's total revenue for the reporting period was CNY 100.8 million, with overseas revenue accounting for CNY 93.2 million, representing 92.45% of total revenue[66]. - The company reported a net profit of CNY 15,934,474.27, down 20.49% from CNY 20,041,723.48 in the previous year[47]. - The company's total liabilities decreased, leading to a significant reduction in financial expenses by 2.42%[47]. Research and Development - The company’s R&D expenses amounted to ¥1,107.28 million, accounting for 10.98% of total revenue, with a focus on enhancing product development and innovation[36]. - Research and development expenses increased significantly to ¥10,034,116.97 in the first half of 2023, up from ¥5,842,744.93 in the same period of 2022, marking an increase of about 71.5%[132]. - The company is focusing on product research and market expansion to reduce reliance on tax incentives and improve profitability[65]. Market Trends and Opportunities - The global hearing aid market is highly monopolized, with the top five brands holding significant market share and advanced core technologies[39]. - The penetration rate of hearing aids in China is currently below 5%, compared to over 20% in many European countries and 14.4% in Japan, indicating significant growth potential[39]. - The introduction of OTC hearing aids by the FDA is expected to create a new growth market and enhance global hearing aid penetration[40]. - By 2025, China's hearing aid market is expected to reach 8.07 billion RMB[39]. - The World Health Organization predicts that by 2050, approximately 2.5 billion people globally will be affected by hearing loss, with 700 million needing medical services[39]. Corporate Governance and Compliance - The company emphasizes the importance of accurate and complete financial reporting, with key personnel guaranteeing the report's integrity[10]. - The company has been recognized as a high-tech enterprise, benefiting from a 15% preferential tax rate for three years[65]. - The company is committed to enhancing its corporate governance structure to mitigate risks associated with actual controllers[65]. - The company will ensure that any related party transactions are conducted at market prices and comply with legal requirements to protect shareholder interests[80]. - The company will notify immediately of any competitive business opportunities obtained from third parties and will strive to pass them to the company[78]. Shareholder and Equity Management - The company has granted a total of 675,000 restricted shares and 945,000 stock options under the 2022 equity incentive plan, with 181,800 shares having been released from restrictions[75]. - As of June 30, 2023, the company has repurchased a total of 352,957 shares, accounting for 31.33% of the planned repurchase amount, with a total expenditure of CNY 5.37 million[77]. - The company will ensure transparency in information disclosure regarding any share reductions planned by its major shareholders[82]. - The company will initiate stock price stabilization measures if the stock price closes below the issuance price for 10 consecutive trading days within the first month after listing[83]. - The controlling shareholder and actual controller will increase their holdings, with a minimum investment of 20% of the previous year's cash dividends and a maximum of 50%[84]. Employee and Community Engagement - The company has absorbed 30 employees from impoverished areas to support poverty alleviation and rural revitalization efforts[61]. - The company organized multiple public welfare activities, including health check-ups in Sichuan and Guizhou provinces[63]. - The company plans to optimize its talent pool and improve working conditions to retain core employees[119]. Financial Instruments and Accounting Policies - The company recognizes expected liabilities in its financial statements[155]. - The company classifies financial assets based on the business model and contractual cash flow characteristics, with specific criteria for measuring at amortized cost or fair value[185]. - Financial liabilities are classified at initial recognition as either at fair value through profit or loss or at amortized cost, with no reclassification allowed[187]. - The company assesses the fair value of financial instruments using active market quotes when available, or valuation techniques such as market, income, and cost approaches when not[193].

证券代码：872925 证券简称：锦好医疗 公告编号：2023-045 惠州市锦好医疗科技股份有限公司 关于接待机构投资者调研情况的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 惠州市锦好医疗科技股份有限公司（以下简称"公司"）于 2023 年 5 月 11 日接待了 2 家机构的调研，现将主要情况公告如下： 一、 调研情况 调研时间：2023 年 5 月 11 日 调研地点：公司 调研形式：现场调研 调研机构：上海申银万国证券研究所有限公司、东海证券股份有限公司 上市公司接待人员：董事会秘书 段皓龄 二、 调研的主要问题及公司回复概要 问题 1：公司哪些产品用自主芯片，哪些产品用外购的芯片？用公司自主芯 片成本能降低多少？ 回答 1：公司多款数字助听器都应用了自主研发的芯片，模拟助听器未来也 将逐步应用自主芯片，进行数字化改进，公司同时仍会积极外购芯片，使用何种 芯片主要是根据客户和市场的需求来决定。自主芯片相较进口芯片，成本大约能 降低三分之二左右。 问题 2：数字助听器和模拟助听器之间有多 ...

证券代码：872925 证券简称：锦好医疗 公告编号：2023-037 惠州市锦好医疗科技股份有限公司 2022 年年度报告说明会预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 说明会类型 惠州市锦好医疗科技股份有限公司（以下简称"公司"）2023 年 4 月 17 日 在北京证券交易所信息披露平台（www.bse.cn）披露了《2022 年年度报告》（公 告编号：2023-016）及《2022 年年度报告摘要》（公告编号：2023-017），为方 便广大投资者更深入了解公司 2022 年年度经营业绩的具体情况，加强与投资者 的交流互动，公司拟召开 2022 年年度报告业绩说明会。 二、 说明会召开的时间、地点 （一）会议召开时间：2023 年 5 月 10 日（星期三）15:00-17:00。 （二）会议召开地点 本次年度报告业绩说明会将采用网络方式召开，投资者可登陆全景网"投资 者 关 系 互 动 平 台 "（ http://ir.p5w.net ） 及 中 证 网 " 中 证 路 ...

Financial Performance - Operating revenue for the first quarter of 2023 reached CNY 59.37 million, representing a year-on-year growth of 57.49% from CNY 37.69 million[10] - Net profit attributable to shareholders for the first quarter of 2023 was CNY 11.22 million, a significant increase of 100.74% compared to CNY 5.59 million in the same period last year[10] - The gross profit margin improved due to an increase in the sales proportion of hearing aids, leading to a 132.12% increase in operating profit to CNY 13.25 million[17] - Total revenue for Q1 2023 reached ¥59,366,785.38, a significant increase from ¥37,694,584.15 in Q1 2022, representing a growth of approximately 57.5%[49] - The net profit for Q1 2023 reached 12,005,443.63 yuan, compared to 5,365,879.18 yuan in Q1 2022, indicating a year-over-year increase of about 123.5%[51] - The total profit for Q1 2023 was 13,258,282.80 yuan, up from 5,948,961.20 yuan in Q1 2022, reflecting an increase of approximately 122.5%[51] Cash Flow - The company's cash flow from operating activities for the first quarter was CNY 6.08 million, down 16.38% from CNY 7.27 million in the previous year[10] - Cash inflow from operating activities for Q1 2023 was CNY 54,310,200.09, an increase of 17.5% compared to CNY 46,223,409.90 in Q1 2022[56] - Net cash flow from operating activities for Q1 2023 was CNY 6,081,517.69, a decrease of 16.4% from CNY 7,272,807.75 in Q1 2022[56] - Cash inflow from investment activities in Q1 2023 was CNY 105,611,289.58, up 77% from CNY 59,722,149.17 in Q1 2022[57] - Net cash flow from investment activities for Q1 2023 was CNY 13,562,348.45, a significant recovery from a negative CNY 34,038,114.12 in Q1 2022[57] Assets and Liabilities - Total assets as of March 31, 2023, amounted to CNY 449.90 million, an increase of 7.72% compared to CNY 417.66 million at the end of 2022[10] - The company's asset-liability ratio (consolidated) increased to 17.34% from 12.67% year-on-year, indicating a rise in leverage[10] - Total liabilities rose to ¥78,011,395.98 in Q1 2023, up from ¥52,905,039.28 in Q4 2022, indicating an increase of approximately 47.8%[43] - Current liabilities totaled ¥72,255,980.83 as of March 31, 2023, compared to ¥47,506,643.47 at the end of 2022, marking a rise of around 51.9%[43] - Non-current assets amounted to ¥259,504,061.89 as of March 31, 2023, up from ¥230,673,684.25 at the end of 2022, showing an increase of about 12.5%[43] Shareholder Information - The total number of unrestricted shares is 27,667,955, representing 56.15% of the total share capital[23] - The total number of restricted shares is 21,607,045, representing 43.85% of the total share capital[23] - The largest shareholder, Wang Min, holds 12,703,057 shares, accounting for 25.78% of the total shares[26] - The second-largest shareholder, Wang Fang, holds 9,526,818 shares, accounting for 19.33% of the total shares[26] - The company has a total share capital of 49,275,000 shares[23] Research and Development - Research and development expenses for the quarter were CNY 5.09 million, reflecting a 67.36% increase, indicating a continued commitment to R&D investment[16] - Research and development expenses for Q1 2023 amounted to 5,091,791.65 yuan, up from 3,042,481.56 yuan in Q1 2022, reflecting a growth of approximately 67.1%[50] Market Strategy - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[49] - The company is actively pursuing strategies for market expansion and new product development as part of its growth initiatives[36] Legal and Compliance - The company has not reported any significant legal disputes or external guarantees during the reporting period[29] - The company has committed to ensuring accurate information disclosure and has stated that there are no false records or misleading statements in its public disclosures[37]